Management   |   Patient advice   |   Grading

 

Adverse event management: diarrhoea

Management recommendations1,2

Approach to management depends on which grade is identified in each patient. A breakdown of the management guidelines is displayed below.

 

Grade 1–2:

  • GIOTRIF® (afatinib) treatment is continued at the same dose
  • Patients should be followed closely to avoid dehydration
  • Patients should stop taking laxatives and drink 8–10 glasses of water or clear fluids per day
  • Patients should make dietary changes, as described in the “Advice for Patients” subsection below
  • Start immediately on loperamide. Initially with a dose of 4 mg, then 2 mg after each episode of diarrhoea
    (up to 20 mg/day) until bowel movements cease for 12 hours

 

If Grade 2 diarrhoea persists longer than 48 hours or is intolerable:

  • Continue loperamide treatment
  • Interrupt GIOTRIF® (afatinib) treatment, restarting once diarrhoea symptoms have resolved to Grade ≤1 at a dose reduced by 10 mg to a minimum of 20 mg/day
  • Assess patients for dehydration and electrolyte imbalance and consider intravenous fluids and electrolyte replacement

 

Grade 3–4:

  • Continue loperamide treatment
  • Interrupt GIOTRIF® (afatinib) treatment, restarting once diarrhoea symptoms have resolved to Grade ≤1 at a dose reduced by 10 mg to a minimum of 20 mg/day
  • Admit patient to hospital to monitor progress and to take stool specimen for microbiologic examination
  • Initiate intravenous fluid replacement for ≥24 hours, noting that substantial fluid loss may have occurred
  • Consider prophylactic antibiotics if the patient is neutropenic

 

If diarrhoea symptoms do not resolve to grade ≤1 within 14 days, despite optimal supportive care and treatment interruption:

  • Permanently discontinue GIOTRIF® (afatinib) treatment

Advice for patients1

  • Drink ≥2 L of clear fluids daily to avoid dehydration; some fluids should contain sugar or salt to avoid electrolyte loss
  • Incorporate bananas, rice, apple sauce and toast into their diet (BRAT diet)
  • Avoid food that exacerbates symptoms (e.g. greasy, spicy and fried foods) are difficult to digest or contain lactose/caffeine

Grading3

The diarrhoea grade can be used to guide the management strategy.

Grade 1 

Grade 2

Grade 3

Grade 4

Increase of <4 stools per day over baseline; mild increase in ostomy output compared to baseline

Increase of 4–6 stools per day over baseline; IV fluids indicated <24hrs; moderate increase in ostomy output compared to baseline; not interfering with ADL

 

Increase of ≥7 stools per day over baseline; incontinence; IV fluids ≥24hrs; hospitalisation; severe increase in ostomy output compared to baseline; interfering with ADL

Life-threatening consequences (e.g. haemodynamic collapse)

Grade 1 

Increase of <4 stools per day over baseline; mild increase in ostomy output compared to baseline

Grade 2

Increase of 4–6 stools per day over baseline; IV fluids indicated <24hrs; moderate increase in ostomy output compared to baseline; not interfering with ADL

 

Grade 3

Increase of ≥7 stools per day over baseline; incontinence; IV fluids ≥24hrs; hospitalisation; severe increase in ostomy output compared to baseline; interfering with ADL

Grade 4

Life-threatening consequences (e.g. haemodynamic collapse)

 

Adapted from CTCAE version 3.3


ADL=activities of daily living, CTCAE=Common Terminology Criteria for Adverse Events


References

1
Yang JC, et al. Expert Rev Anticancer Ther 2013;13(6):729–736.
2
GIOTRIF® (afatinib) Summary of Product Characteristics, 2018.
3
Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.

Back to top

This site uses cookies to improve your browsing experience. By using this site, you agree to their use.

Cookie policy
I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information about afatinib for non-small-cell lung cancer treatment.

Country-specific product information

Country-specific product information

Click here for country-specific product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.